-
Je něco špatně v tomto záznamu ?
Dynamics of serum levels of tumour markers and prognosis of recurrence and survival after liver surgery for colorectal liver metastases
Liska V, Holubec L Jr, Treska V, Skalicky T, Sutnar A, Kormunda S, Pesta M, Finek J, Rousarova M, Topolcan O.
Jazyk angličtina Země Řecko
Grantová podpora
NR7905
MZ0
CEP - Centrální evidence projektů
NR8301
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Část
Plný text - Část
Zdroj
Zdroj
NLK
Free Medical Journals
od 2004 do Před 2 roky
Open Access Digital Library
od 2004-01-01
- MeSH
- financování organizované MeSH
- kolorektální nádory krev patologie MeSH
- lidé MeSH
- lokální recidiva nádoru krev patologie MeSH
- míra přežití MeSH
- nádorové biomarkery krev MeSH
- nádory jater chirurgie krev sekundární MeSH
- přežití bez známek nemoci MeSH
- retrospektivní studie MeSH
- Check Tag
- lidé MeSH
BACKGROUND: The authors present a statistical analysis of the dynamics of tumour markers and compare these with single serum levels in patients before and after liver surgery for colorectal liver metastases (CLM). PATIENTS AND METHODS: The serum levels of tumor markers conventionally used in clinical practice (CA19-9, CEA, CA72-4) and markers informing of the proliferation activity of malignancy (TKI TPA, TPS) were statistically analysed. The authors studied 144 patients who underwent liver surgery for colorectal liver metastases between September 1999 and June 2005. Serum levels of tumor markers before surgery (maximally two weeks before the operation), after surgery (maximally one month after the operation - usually on the day of dismission), six months (+/- one month) and twelve months after the surgery (+/- one month) were determined. The Log Rank test and the Wilcoxon test were used for statistical evaluation. The survival rate and disease-free intervals (DFI) were computed using the Kaplan-Meier method. RESULTS: The statistical analysis of tumour marker dynamic after liver surgery (speed and power of recurrence) supported the dynamics of CA 19-9 and CEA as excellent prognostic factors of early recurrence of CLM in contrast to proliferative tumor markers. CONCLUSION: The results of the study suggest the importance of tumour markers for the prediction of a short survival rate or DFI. This approach would be very helpful for the planning of palliative oncological treatment for patients with liver malignancies that cannot be treated by surgical therapy. Current patients with a high tendency of recurrence of CLM after liver surgery should be followed up more thoroughly to increase the possibility of successful reoperation.
- 000
- 00000naa 2200000 a 4500
- 001
- bmc10000818
- 003
- CZ-PrNML
- 005
- 20131010100534.0
- 008
- 100114s2007 gr e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Liška, Václav, $d 1978- $7 xx0073943
- 245 10
- $a Dynamics of serum levels of tumour markers and prognosis of recurrence and survival after liver surgery for colorectal liver metastases / $c Liska V, Holubec L Jr, Treska V, Skalicky T, Sutnar A, Kormunda S, Pesta M, Finek J, Rousarova M, Topolcan O.
- 314 __
- $a Department of Surgery, University Hospital Pilsen, Charles University Prague, Alej svobody 80, 323 00 Pilsen, Czech Republic. Vena.liska@seznam.cz
- 520 9_
- $a BACKGROUND: The authors present a statistical analysis of the dynamics of tumour markers and compare these with single serum levels in patients before and after liver surgery for colorectal liver metastases (CLM). PATIENTS AND METHODS: The serum levels of tumor markers conventionally used in clinical practice (CA19-9, CEA, CA72-4) and markers informing of the proliferation activity of malignancy (TKI TPA, TPS) were statistically analysed. The authors studied 144 patients who underwent liver surgery for colorectal liver metastases between September 1999 and June 2005. Serum levels of tumor markers before surgery (maximally two weeks before the operation), after surgery (maximally one month after the operation - usually on the day of dismission), six months (+/- one month) and twelve months after the surgery (+/- one month) were determined. The Log Rank test and the Wilcoxon test were used for statistical evaluation. The survival rate and disease-free intervals (DFI) were computed using the Kaplan-Meier method. RESULTS: The statistical analysis of tumour marker dynamic after liver surgery (speed and power of recurrence) supported the dynamics of CA 19-9 and CEA as excellent prognostic factors of early recurrence of CLM in contrast to proliferative tumor markers. CONCLUSION: The results of the study suggest the importance of tumour markers for the prediction of a short survival rate or DFI. This approach would be very helpful for the planning of palliative oncological treatment for patients with liver malignancies that cannot be treated by surgical therapy. Current patients with a high tendency of recurrence of CLM after liver surgery should be followed up more thoroughly to increase the possibility of successful reoperation.
- 650 _2
- $a financování organizované $7 D005381
- 650 _2
- $a kolorektální nádory $x krev $x patologie $7 D015179
- 650 _2
- $a přežití bez známek nemoci $7 D018572
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nádory jater $x chirurgie $x krev $x sekundární $7 D008113
- 650 _2
- $a lokální recidiva nádoru $x krev $x patologie $7 D009364
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a míra přežití $7 D015996
- 650 _2
- $a nádorové biomarkery $x krev $7 D014408
- 700 1_
- $a Holubec, Luboš, $d 1972- $7 xx0068645
- 700 1_
- $a Třeška, Vladislav, $d 1957- $7 jn20000402436
- 700 1_
- $a Skalický, Tomáš, $d 1965- $7 xx0017169
- 700 1_
- $a Sutnar, Alan $7 xx0081862
- 700 1_
- $a Kormunda, Stanislav $7 xx0103970
- 700 1_
- $a Pešta, Martin, $d 1976- $7 xx0073915
- 700 1_
- $a Fínek, Jindřich, $d 1957- $7 xx0026897
- 700 1_
- $a Roušarová, Milena. $7 jo2015860324
- 700 1_
- $a Topolčan, Ondřej, $d 1943- $7 jn20000402383
- 773 0_
- $w MED00000478 $t Anticancer research $g Roč. 27, č. 4C (2007), s. 2861-2864 $x 0250-7005
- 910 __
- $a ABA008 $b x $y 8 $z 0
- 990 __
- $a 20090310084605 $b ABA008
- 991 __
- $a 20131010101057 $b ABA008
- 999 __
- $a ok $b bmc $g 703546 $s 565986
- BAS __
- $a 3
- BMC __
- $a 2007 $b 27 $c 4C $d 2861-2864 $i 0250-7005 $m Anticancer research $x MED00000478
- GRA __
- $a NR7905 $p MZ0
- GRA __
- $a NR8301 $p MZ0
- LZP __
- $a 2010-b1/ipme